Microarray Patch Based Transdermal Allergen Immunotherapy Prevents Gliadin-induced Anaphylaxis in a Murine Model.

IF 4.1 2区 医学 Q2 ALLERGY
Lin Liang, Ah-Reum Hwang, Tae Eun Guon, Kyung Hee Park, Chang Ook Park, Jae-Hyun Lee, Jung-Won Park
{"title":"Microarray Patch Based Transdermal Allergen Immunotherapy Prevents Gliadin-induced Anaphylaxis in a Murine Model.","authors":"Lin Liang, Ah-Reum Hwang, Tae Eun Guon, Kyung Hee Park, Chang Ook Park, Jae-Hyun Lee, Jung-Won Park","doi":"10.4168/aair.2025.17.3.330","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Gliadins are the primary triggers in wheat-dependent exercise-induced anaphylaxis. Currently, there are no officially approved immune-modulating treatments for gliadin allergy. Recent <i>in vivo</i> studies have shown that hyaluronic acid based dissolving microarray patch (dMAP) could deliver house dust mite allergens through transdermal pathway and protect allergic asthma and atopic dermatitis <i>in vivo.</i> In this study, we explored the potential of dMAP for the transdermal delivery of gliadin proteins as a strategy to mitigate gliadin allergy.</p><p><strong>Methods: </strong>C3H/HeJ mice were sensitized to gliadin with cholera toxin via oral administration, followed by oral or intraperitoneal gliadin challenge. To evaluate the protective effects of transdermal immunotherapy (TDIT), gliadin-loaded dMAPs were applied twice a week to gliadin-sensitized mice for 4 weeks. Afterward, the mice were challenged with gliadin.</p><p><strong>Results: </strong>The manufacturing process of dMAP did not alter the allergenicity of gliadin. TDIT significantly improved the anaphylaxis clinical score and stabilized core body temperature in the gliadin anaphylaxis model. It reduced mast cell protease-1 and gliadin-specific immunoglobulin E (IgE), and increased specific IgG₁, IgG<sub>2a</sub> and IgG<sub>2b</sub> levels. <i>Ex vivo</i> splenocyte study revealed that TDIT enhanced T helper type 1 (Th₁) cell population, interferon-γ expression, regulatory T cell population, and interleukin (IL)-10 expression, as well as suppressed Th₂ cell population and associated cytokines (IL-4, IL-5, and IL-13). Furthermore, this TDIT preserved the structural integrity of small intestinal villi and reduced eosinophil and mast cell infiltration.</p><p><strong>Conclusions: </strong>Gliadin TDIT using dMAP mitigates gliadin-induced anaphylaxis in a murine model, offering a promising novel immune modulating treatment for gliadin-induced anaphylaxis.</p>","PeriodicalId":7547,"journal":{"name":"Allergy, Asthma & Immunology Research","volume":"17 3","pages":"330-348"},"PeriodicalIF":4.1000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12117480/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergy, Asthma & Immunology Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4168/aair.2025.17.3.330","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Gliadins are the primary triggers in wheat-dependent exercise-induced anaphylaxis. Currently, there are no officially approved immune-modulating treatments for gliadin allergy. Recent in vivo studies have shown that hyaluronic acid based dissolving microarray patch (dMAP) could deliver house dust mite allergens through transdermal pathway and protect allergic asthma and atopic dermatitis in vivo. In this study, we explored the potential of dMAP for the transdermal delivery of gliadin proteins as a strategy to mitigate gliadin allergy.

Methods: C3H/HeJ mice were sensitized to gliadin with cholera toxin via oral administration, followed by oral or intraperitoneal gliadin challenge. To evaluate the protective effects of transdermal immunotherapy (TDIT), gliadin-loaded dMAPs were applied twice a week to gliadin-sensitized mice for 4 weeks. Afterward, the mice were challenged with gliadin.

Results: The manufacturing process of dMAP did not alter the allergenicity of gliadin. TDIT significantly improved the anaphylaxis clinical score and stabilized core body temperature in the gliadin anaphylaxis model. It reduced mast cell protease-1 and gliadin-specific immunoglobulin E (IgE), and increased specific IgG₁, IgG2a and IgG2b levels. Ex vivo splenocyte study revealed that TDIT enhanced T helper type 1 (Th₁) cell population, interferon-γ expression, regulatory T cell population, and interleukin (IL)-10 expression, as well as suppressed Th₂ cell population and associated cytokines (IL-4, IL-5, and IL-13). Furthermore, this TDIT preserved the structural integrity of small intestinal villi and reduced eosinophil and mast cell infiltration.

Conclusions: Gliadin TDIT using dMAP mitigates gliadin-induced anaphylaxis in a murine model, offering a promising novel immune modulating treatment for gliadin-induced anaphylaxis.

基于微阵列贴片的透皮过敏原免疫疗法在小鼠模型中预防麦胶蛋白诱导的过敏反应。
目的:麦胶蛋白是小麦依赖性运动致过敏反应的主要诱因。目前,还没有官方批准的免疫调节治疗麦胶蛋白过敏。最近的体内研究表明,基于透明质酸的溶解微阵列贴片(dMAP)可以通过透皮途径递送屋尘螨过敏原,并在体内保护过敏性哮喘和特应性皮炎。在这项研究中,我们探索了dMAP在麦胶蛋白经皮递送中的潜力,作为减轻麦胶蛋白过敏的一种策略。方法:采用霍乱毒素对C3H/HeJ小鼠口服麦胶蛋白致敏,然后口服或腹腔注射麦胶蛋白。为了评估透皮免疫治疗(TDIT)的保护作用,将装载麦胶蛋白的dMAPs每周两次应用于麦胶蛋白致敏小鼠,持续4周。之后,用麦胶蛋白刺激小鼠。结果:dMAP的制备工艺未改变麦胶蛋白的致敏性。在麦胶蛋白过敏反应模型中,TDIT显著提高了过敏反应临床评分,稳定了核心体温。降低肥大细胞蛋白酶-1和麦胶蛋白特异性免疫球蛋白E (IgE),增加特异性IgG 1、IgG2a和IgG2b水平。体外脾细胞研究显示,TDIT增强了辅助性T型1 (Th₁)细胞群、干扰素-γ表达、调节性T细胞群和白细胞介素(IL)-10表达,抑制了Th₂细胞群和相关细胞因子(IL-4、IL-5和IL-13)。此外,TDIT保留了小肠绒毛的结构完整性,减少了嗜酸性粒细胞和肥大细胞的浸润。结论:在小鼠模型中,使用dMAP的麦胶蛋白TDIT减轻了麦胶蛋白诱导的过敏反应,为麦胶蛋白诱导的过敏反应提供了一种有希望的新型免疫调节治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.10
自引率
6.80%
发文量
53
审稿时长
>12 weeks
期刊介绍: The journal features cutting-edge original research, brief communications, and state-of-the-art reviews in the specialties of allergy, asthma, and immunology, including clinical and experimental studies and instructive case reports. Contemporary reviews summarize information on topics for researchers and physicians in the fields of allergy and immunology. As of January 2017, AAIR do not accept case reports. However, if it is a clinically important case, authors can submit it in the form of letter to the Editor. Editorials and letters to the Editor explore controversial issues and encourage further discussion among physicians dealing with allergy, immunology, pediatric respirology, and related medical fields. AAIR also features topics in practice and management and recent advances in equipment and techniques for clinicians concerned with clinical manifestations of allergies and pediatric respiratory diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信